Neuland Labs Q1FY27: Income surges 116% to ₹650 Cr, PAT up 975% to ₹147 Cr
Neuland Laboratories reported a strong Q1FY27 with total income soaring 116.3% YoY to ₹650.1 crore. PAT surged 975% to ₹147.4 crore, and EBITDA grew 448.2% to ₹231.1 crore. The company invested ₹122 crore in capex and saw working capital days reduce to 84.
The substantial increase in key financial metrics like revenue, EBITDA, and PAT, along with strategic commentary on future investments and business growth, is expected to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in total income, EBITDA, and PAT, along with improved working capital efficiency and substantial capital expenditure, indicating strong operational performance and future growth prospects.
Neuland Laboratories Limited has announced its financial results for the first quarter of Fiscal Year 2027 (Q1FY27), ending June 30, 2026. The company reported a significant increase in total income, which rose by 116.3% year-on-year to ₹650.1 crore, compared to ₹300.6 crore in Q1FY26. This growth was primarily driven by strong performance in both the Custom Manufacturing Solutions (CMS) and Generic Drug Substance (GDS) businesses.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a substantial jump of 448.2% to ₹231.1 crore, with the EBITDA margin expanding by 2150 basis points to 35.5% from 14.0% in the prior year quarter. Profit After Tax (PAT) witnessed a remarkable surge of 975.0% to ₹147.4 crore, up from ₹13.7 crore in Q1FY26. Consequently, Earnings Per Share (EPS) grew by 975.0% to ₹114.9 from ₹10.7 in the same period.
The company also reported improvements in working capital, with days of sales decreasing to 84 days in Q1FY27 from 137 days in Q4FY26, mainly due to a reduction in receivables. Capital expenditure outflow for the quarter was ₹122 crore. The management, through its CEO & MD Saharsh Davuluri, expressed optimism about the quarter being in line with expectations, highlighting encouraging performance from both CMS and GDS businesses and a strong pipeline for future projects. The company is focusing on consistent delivery, building customer confidence, and establishing long-term partnerships, with an expectation of increased investment based on available opportunities.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.